Stem cell and gene therapy for cardiovascular disease /
General Material Designation
[Book]
First Statement of Responsibility
edited by Emerson C. Perin, M.D., Ph.D., FACC, Leslie W. Miller, M.D., Doris A. Taylor, Ph.D., FAHA, FACC, James T. Willerson, M.D., FAHA, FACC
PHYSICAL DESCRIPTION
Specific Material Designation and Extent of Item
xxii, 515 pages :
Other Physical Details
illustrations (chiefly color) ;
Dimensions
28 cm
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references and index
CONTENTS NOTE
Text of Note
Intravenous, intracoronary, transendocardial, and advential delivery -- Retrograde coronary sinus delivery for cardiac cell therapy -- Part II. Tissue Engineering: Current perspectives on methods for administering human pluripotent stem cell-derived cells for myocardial repair -- Acellular injectable biomaterials for treating cardiovascular disease -- Scaffold-based cell delivery for cardiac repair -- Biomaterial: alginate -- Organogenesis -- Part III. Gene Therapy: Gene therapy for cardiovascular diseases -- SERCA2a gene therapy for heart failure -- SDF-1 for cardiac repair -- Gene therapy in critical limb ischemia -- Use of gene modified stem cells for acute myocardial infarction -- Part IV. Future Directions: The history and future of the cardiovascular cell therapy research network -- Signature of responders - lessons from clinical samples -- Adjunctive therapies with LVADs: combining biological and mechanical regenerative therapies -- Trials in non-ischemic heart failure -- New strategies to enhance stem cell homing for tissue repair -- Cell therapy in ischemic stroke
Text of Note
Part I. Stem Cells: Introduction and overview of stem cells -- Pathological assessment of experimental models of stem cell and other regenerative therapies -- Large animal models for cardiac cell therapy -- Role of paracrine mechanisms -- Impact of telomere shortening with age in stem cell therapy: new strategies to increase telomere length -- Peripheral arterial disease -- Cell therapy for refractory angina -- Stem cell therapy for acute myocardial infarction: the European experience -- Acute myocardial infarction: the United States experience -- Autologous bone marrow cells for chronic ischemic heart failure -- Adipose-derived stem cells -- Mesenchymal stem cells -- Allogeneic versus autologous source: comparative effects -- Allogeneic alternatives to autologous bone marrow: the MSC clinical trials of acute MI with MSCs -- Allogenic alternatives to autologous bone marrow: the MSC combined cell strategies -- Therapy with c-kit cardiac stem cells for ischemic cardiomyopathy -- Cardiosphere-derived cells -- Cardiovascular regenerative cell therapy using umbilical cord and endometrial cells -- Cardiopoietic stem cells for heart failure therapy -- Transformation to inductible pluripotent stem cells -- Multipotent adult progenitor cells (MAPCs) for cardiovascular and neurologic diseases